JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 80 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $17,000 | – | 2,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 4,447,829 | $30,245,000 | 89.29% |
| TRV GP III, LLC | 3,048,780 | $20,732,000 | 3.62% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 250,644 | $1,704,000 | 0.76% |
| PFM Health Sciences, LP | 3,262,833 | $22,187,000 | 0.70% |
| Yorktown Management & Research Co Inc | 56,600 | $385,000 | 0.30% |
| Sofinnova Investments, Inc. | 624,756 | $4,248,000 | 0.24% |
| Omega Fund Management, LLC | 275,513 | $1,873,000 | 0.21% |
| PATHWAY CAPITAL MANAGEMENT, LP | 60,279 | $410,000 | 0.16% |
| Orbimed Advisors | 2,147,400 | $14,602,000 | 0.15% |
| Grace Capital | 18,669 | $127,000 | 0.08% |